Limbach's shares plunged 37.8% post-earnings, reflecting investor disappointment with ongoing margin pressure and project timing issues that led to results falling short of expectations. The weak performance was exacerbated by softness in health and institutional markets and cautious near-term outlook despite strategic diversification efforts.
Limbach’s shares dropped sharply by 35% as investors reacted negatively to organic revenue decline, continued margin compression, and cautious outlook despite strong bookings and stable adjusted EBITDA.
Limbach Holdings reported strong growth in its third quarter of 2025, driven by an increasing shift toward owner-direct relationships and enhanced service offerings, contributing to improved revenue stability and margin consistency.